We use cookies to customise content for your subscription and for analytics. If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
The Federal Court of Canada has recently held that a drug previously approved in Canada, but withdrawn for safety reasons, could later qualify as an "innovative drug"
